The Effect of Optimizing Urine Drug Screening Panels at Two Academic Medical Centers
Changes to the UDS panel aligned laboratory testing with patterns of drug use and clinical utility and standardized care within our healthcare system. Unnecessary testing was reduced; drugs removed from the panel were infrequently ordered.
Authors
- Timothy B. Erickson (ORCID: https://orcid.org/0000-0002-1809-4805)
- Grace K. Mahowald (ORCID: https://orcid.org/0000-0003-4541-4920)
- Phillip Kang
- Stacy E.F. Melanson (ORCID: https://orcid.org/0000-0002-4209-6085)
- Nicole V. Tolan (ORCID: https://orcid.org/0000-0002-7239-1843)
- Alex Chin
- Sacha Uljon (ORCID: https://orcid.org/0000-0001-5190-6652)
- Peter R Chai
Institutions
- Brigham and Women's Hospital (US)
- Harvard University (US)
- Dana-Farber/Harvard Cancer Center (US)
- Fenway Health (US)
- Mass General Brigham (US)
- Massachusetts Institute of Technology (US)
Publication Details
- Journal
- The Journal of Applied Laboratory Medicine
- Published
- 2026-02-11
- DOI
- https://doi.org/10.1093/jalm/jfag026
- Primary Topic
- Pharmaceutical Practices and Patient Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 0.00